维生素K拮抗剂患者轻度创伤性脑损伤后系统逆转:凝血酶原复合物浓缩物随机对照试验
PREVACT研究为在21家法国急诊科开展的多中心随机开放标签盲法终点临床试验,纳入服用维生素K拮抗剂、6小时内发生创伤性脑损伤且格拉斯哥昏迷评分≥13分的患者。患者随机分为干预组(任何检查前立即给予25 IU/kg四因子凝血酶原复合物浓缩物系统逆转)和对照组(标准治疗,仅在初始头颅CT提示颅内出血时逆转)。主要终点为纳入后24小时头颅CT检出的颅内出血率。研究因后勤原因在随机化202例患者后提前终止,干预组98例中6例(6.1%)出现颅内出血,对照组99例中12例(12.1%),OR 0.47(95%CI 0.14-1.44,P=0.215),未达统计学显著。作者认为,该研究提前终止,不能排除该策略具有临床相关获益。
要点
- 研究因后勤原因在随机化202例后提前终止,干预组101例、对照组101例,主要终点分析干预组98例、对照组99例。
- 24小时头颅CT颅内出血率:干预组6.1%(6/98)vs 对照组12.1%(12/99),OR 0.47(95%CI 0.14-1.44),P=0.215,未达统计学显著。
- 纳入标准:服用维生素K拮抗剂、6小时内发生创伤性脑损伤、格拉斯哥昏迷评分≥13分。
- 干预方案:任何检查前立即给予25 IU/kg四因子凝血酶原复合物浓缩物;对照组仅在初始头颅CT提示颅内出血时逆转。
- 作者认为研究提前终止,不能排除该策略具有临床相关获益。
适用人群与场景
- 服用维生素K拮抗剂、6小时内发生创伤性脑损伤、格拉斯哥昏迷评分≥13分的患者,就诊于急诊科。
诊断标准与关键阈值
- 纳入标准:正在接受维生素K拮抗剂治疗;6小时内发生创伤性脑损伤;格拉斯哥昏迷评分≥13分。
处置流程与药物剂量
- 干预组:在任何检查前立即给予25 IU/kg四因子凝血酶原复合物浓缩物进行系统逆转。
- 对照组:标准治疗,仅在初始头颅CT扫描提示颅内出血时进行逆转。
研究设计与关键结果
- 研究类型:随机、开放标签、盲法终点临床试验,在21家法国急诊科开展。
- 样本量:计划随机化202例,干预组101例、对照组101例;主要终点分析干预组98例、对照组99例;平均年龄90岁,女性51.8%。
- 主要终点:纳入后24小时头颅CT检出的颅内出血率,干预组6.1%(6/98)vs 对照组12.1%(12/99),OR 0.47(95%CI 0.14-1.44),P=0.215,未达统计学显著。
- 研究因后勤原因在随机化202例后提前终止。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 局限:研究因后勤原因提前终止;作者认为不能排除该策略具有临床相关获益。
对床旁实践的改变
- 作者认为,在近期轻度创伤性脑损伤且服用维生素K拮抗剂的患者中,系统立即给予25 IU/kg四因子凝血酶原复合物浓缩物未在统计学上显著降低24小时颅内出血率,但研究提前终止,不能排除该策略具有临床相关获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: Traumatic brain injury (TBI) in patients on vitamin K antagonists (VKAs) is linked to a high rate of intracranial hemorrhage (ICH). Rapid reversal can reduce ICH progression and mortality, but its effectiveness depends on the time between bleeding onset and coagulation normalization.
OBJECTIVE: The PREVACT study aimed to assess the efficacy and safety of prompt systematic reversal of anticoagulation in patients presenting to emergency departments (EDs) for recent mild-TBI while receiving a VKA.
INTERVENTION: A randomized, open-label, blinded-endpoint clinical trial was conducted in 21 French EDs. Patients receiving a VKA, having experienced a TBI within the last 6 h, and presenting a Glasgow Coma Score ≥13 were included. Patients were randomized to systematic immediate VKA reversal with 25 IU/kg of four-factor prothrombin complex concentrate (4f-PCC) before any investigation (intervention group) or standard-of-care signifying reversal only if the initial cranial computed tomography (CT) scan indicated ICH (control group). The primary outcome was the rate of ICH detected on a cranial CT scan 24 h post-inclusion.
RESULTS: The study was prematurely stopped for logistic reasons after the randomization of 202 patients (101 and 101 in the intervention and control groups, respectively, mean age 90; 51.8% female). On the 24-h cranial CT scan, 6 of 98 patients (6.1%) in the intervention group manifested ICH vs. 12 of 99 patients (12.1%) in the control group [odds ratio: 0.47 (95% confidence interval: 0.14-1.44); P = 0.215].
CONCLUSION: In patients with recent mild-TBI receiving a VKA, systematic prompt reversal with 4f-PCC did not statistically significantly reduce ICH rate at 24 h. However, the study was prematurely stopped and does not exclude a clinically relevant benefit of the strategy tested.
TRIAL REGISTRATION: Clinicaltrials.gov (NCT01961804).
参考来源
- Douillet D, Tazarourte K, Dehours E, et al. Systematic vitamin K antagonist reversal with prothrombin complex concentrate in patients with mild traumatic brain injury: randomized controlled trial. Eur J Emerg Med. 2024. PMID: 40315031. doi:10.1097/MEJ.0000000000001199
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。